Passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders


Agios (NASDAQ: AGIO) is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging the company’s knowledge of metabolism, biology and genomics.


Year Invested: 2008
Location: Cambridge, Mass.
Visit: www.agios.com

Recent News

April 18, 2017
Agios Announces Pricing of $250 Million Public Offering of Common Stock

April 17, 2017
Agios Announces Proposed Offering of Common Stock

March 30, 2017
Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017

Read More News

Associated Team Members

Kevin Starr
Partner

Craig Muir
Partner/Chief Technology Officer

Cary Pfeffer, M.D.
Partner